Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men

Summary

This study is designed as a 2-part study, with Part 1 being open-label to best determine the appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo controlled design. The study aims to assess the safety and tolerability of BGS649, and determine whether or not BGS649 is able to normalize testosterone levels and improve insulin sensitivity in obese, hypogonadotropic hypogonadal (OHH) men

Timeline

Start

2010-08

Primary completion

2012-08

Completion

2012-08

Drugs

Indications

No indication recorded.